The observation that the effect of MET, ASP, and their combination is very distinct in HT-29 cells (which possess mutated PI3KCA) and Caco-2 cells (which possess wild-type PI3KCA) led us to hypothesize that inhibition of the PI3K pathway may be the common mechanism involved in the anti-CRC effect of both these drugs. Here, PIK3CA is linked to colorectal carcinoma.